Sovereign starts PFS at Malingunde graphite project

|

Published 13-NOV-2017 11:56 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

This product is classified as ‘very high risk’ in nature due to its location and geopolitical situation of the region. FinFeed advises that extra caution should be taken when deciding whether to engage in this product, however if you are not sure whether it is suitable for you we suggest you seek independent financial advice.

Sovereign Metals Limited (ASX:SVM) today announced it had commenced the Pre-feasibility Study for the low-cost Malingunde saprolite-hosted graphite project in Malawi.

The PFS is intended to build on the promising results that came from the recently completed Scoping Study. That study provided further evidence of the project’s potential to become a very low cost operating mine, producing an annual graphite concentrate production of ~44,000 tonnes over an initial 17 years.

The below graphic indicates the key information gleaned from the Scoping Study at the Malingunde project:

sovereign metals scoping study

SVM is currently fully funded to see it through both the PFS as well as a subsequent DFS (definitive feasibility study), due to a recent A$6.5 million capital raise. It has now appointed the appropriate personnel for both studies, as well as consultants for the metallurgical, environmental, groundwater and tailings aspects of the project.

It should be noted here that SVM remains a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.

Several programs are already underway to ensure the PFS can be fast-tracked to completion by mid-2018, including baseline environmental studies and a metallurgical program. Approximately 6000 metres of resource infill and regional exploration drilling are pegged to start in the near-term.

The purpose of the PFS program will be to increase the resource classification level for the Malingunde mine plan, as well as test a number of the surrounding prospects for high-grade saprolite-hosted graphite mineralisation.

The full scope of the program has now been finalised. It will include mine design; a substantial metallurgical program; process design and engineering works based on metallurgy results; planning of on-site infrastructure requirements; the continuation of environmental baseline studies; and the commencement of a major stakeholder engagement program.

Regarding today’s announcement, SVM Managing Director, Dr Julian Stephens said “Sovereign is now fully funded to complete all the required technical studies on the 100%-owned, world class Malingunde saprolite hosted graphite project in Malawi. The PFS will build on the outcomes of the Scoping Study that clearly demonstrated the Project’s world-class potential centred on very low operating and capital costs, with high revenues derived from a premium graphite product.”

tags

GRAPHITE


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X